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A B S T R A C T
Recent technological advances have led to rapid progress in the characterization of epigenetic
modifications that control gene expression in a generally heritable way, and are likely involved in
defining cellular phenotypes, developmental stages and disease status from one generation to the next.
On November 18, 2013, the International Life Sciences Institute (ILSI) Health and Environmental Sciences
Institute (HESI) held a symposium entitled “Advances in Assessing Adverse Epigenetic Effects of Drugs
and Chemicals” in Washington, D.C. The goal of the symposium was to identify gaps in knowledge and
highlight promising areas of progress that represent opportunities to utilize epigenomic profiling for risk
assessment of drugs and chemicals. Epigenomic profiling has the potential to provide mechanistic
information in toxicological safety assessments; this is especially relevant for the evaluation of
carcinogenic or teratogenic potential and also for drugs that directly target epigenetic modifiers, like DNA
methyltransferases or histone modifying enzymes. Furthermore, it can serve as an endpoint or marker for
hazard characterization in chemical safety assessment. The assessment of epigenetic effects may also be
approached with new model systems that could directly assess transgenerational effects or potentially
sensitive stem cell populations. These would enhance the range of safety assessment tools for evaluating
xenobiotics that perturb the epigenome. Here we provide a brief synopsis of the symposium, update
findings since that time and then highlight potential directions for future collaborative efforts to
incorporate epigenetic profiling into risk assessment.
ã 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The term “epigenetics” has undergone much reinterpretation
since first coined by Conrad Waddington, who proposed that
development and evolution can be viewed as a succession of
relatively stable states, separated by stages of instability and
change (Stern, 2000; Waddington, 1940). A modern molecular
view of epigenetics refers to the induction of stable changes in gene
expression and chromatin organization that are independent of
changes in the DNA sequence and propagated through cell division
(Herceg et al., 2013). Key components involved in epigenetic
mechanisms include DNA methylation, modifications of histone
proteins and expression of non-coding RNA species, as well as
X-chromosome inactivation and genomic imprinting which might
be considered as secondary effects (Ferguson-Smith, 2011).
The fundamental structural unit within the chromatin structure
is the nucleosome, which consists of 146 bp of DNA wrapped
around a nucleosome core that is composed of evolutionary
conserved histone proteins. The subsequent compaction of
nucleosomes packages the DNA in the cell nucleus into character-
istic cytological structures that include heterochromatin (Kouzar-
ides, 2007). The higher order structure of chromatin is important in
the regulation of gene expression with an “open” or euchromatic
state able to facilitate transcription while a compact or hetero-
chromatic state is associated with silenced regions of the genome
(Sproul et al., 2005). Core histones (H2A, H2B, H3, and H4) have
flexible N-terminal domains that contain residues that can be post-
translationally modified at specific sites by methylation, acetyla-
tion, phosphorylation, ubiquitination, and sumoylation (Kouzar-
ides, 2007). Sets of modifications are associated with
transcriptionally active and silent states. Complex interactions
between histones, modifying enzymes, DNA sequences, and other
partner proteins contribute to gene expression regulation in
specific contexts.
Epigenetic modifications can in general be grouped into those
which are either deposited directly onto the DNA or those which
mark the N-terminal tails of histone proteins. They are part of a
complex network of interactions that fine-tune cells to their
environmental conditions. These changes modify the DNA
landscape to qualitatively and quantitatively determine how
proteins interact with DNA segments, and thereby regulate gene
expression globally and locally. Methylation catalyzed by DNAmethyltransferases at the 5th position of cytosine residues in the
context of the CpG dinucleotide results in formation of
5-methylcytosine (5-mC), which decorates the DNA landscape of
mammalian somatic cells (Cruickshanks et al., 2013; Ehrlich et al.,
1982; Jeltsch and Jurkowska, 2014). Methylation of cytosine at
regulatory regions (promoters and enhancers) is associated with
transcriptional repression and is considered to be rather stable in
the genome. Although the majority of CpG dinucleotides are
methylated in somatic DNA, a significant fraction of them, termed
CpG islands (CGIs), are non-modified and are typically promoter
associated (Illingworth et al., 2010).
The pathways governing active removal of 5-mC are only now
beginning to be understood due to the recent discovery of further
modified forms of cytosine nucleotides (Ito et al., 2011; Kriaucionis
and Heintz, 2009). In 2009 the dioxygenase enzymes that convert
5-mC to 5-hydroxymethylcytosine (5-hmC), 5-formyl cytosine
(5-fC) and 5-carboxylcytosine (5-caC) were described (Tahiliani
et al., 2009). In terms of abundance 5-hmC is characteristically
present at 10% or less relative to 5-mC, with 5-fC and 5-caC many
orders of magnitude lower (Pfaffeneder et al., 2014). The attraction
of studying 5-hmC in conjunction with 5-mC is that it is associated
with reprogramming of DNA methylation patterns and is
correlated with active genic regions in multiple tissues (Ficz
et al., 2011; Nestor et al., 2012; Szulwach et al., 2011; Wu and
Zhang, 2014). As such, 5-hmC profiles are indicative of cellular
state (Laird et al., 2013).
In recent decades, the potential for xenobiotics to alter
expression of genes has been well-studied. Termed toxicogenom-
ics, this field endeavors to elucidate molecular mechanisms that
underlie adverse responses to toxic agents by measuring alter-
ations in messenger RNA (mRNA) expression. Such perturbations
may then lead to altered protein expression and activity, thereby
propagating the intracellular response to the agent. Recently
attention has focused on understanding alterations of epigenetic
modification in gene regulatory regions that control expression of
genes. In that context, large epigenomic data sets for multiple
tissues and disease states have been generated over the last decade
that identify characteristic epigenetic alterations in cellular state,
development, disease and cancer (Sproul and Meehan, 2013)
(Fig. 1). Accumulating evidence suggests that epigenetic markers
and/or the molecular machinery regulating them may be
perturbed by exposure to various environmental, chemical, and
Fig. 1. Exploitation of epigenetic datasets. Representative schematic indicating DNA methylation, gene expression and chromatin modification states on a region of mouse
chromosome X (data from (Reddington et al., 2013)). Superimposed are potential avenues for genome wide analysis of epigenome datasets in relation to environmental
exposure studies.
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toxicity viewpoint, this is a possible mechanism of action that links
transient exposure to an inducer to potentially stable cellular
changes including alteration of gene expression. Therefore,
epigenetic parameters have been proposed as biomarkers of
exposure to environmental toxicants and carcinogens (Alyea et al.,
2014; Goodman et al., 2010; Herceg et al., 2013; Koturbash et al.,
2011; Laird et al., 2013). However, significant knowledge gaps exist
that prevent the inclusion of epigenomics data into xenobiotic
hazard characterizations. One ongoing question regards the
determination of whether observed epigenetic alterations are an
outcome of exposure or a direct facilitator of change. In addition,
there is a lack of data agreement regarding which epigenomic
changes are adverse versus those that are merely reactive to a
chemical stimulus. With increasing interest in assessing hazard
potential by measuring subtle, molecular changes in adverse
outcome pathways (AOPs) within both the environmental and
pharmaceutical regulatory agencies, it is critical to identify
which epigenomic changes will be useful to assess and in which
contexts.
On November 18, 2013, the International Life Sciences Institute
(ILSI) Health and Environmental Sciences Institute (HESI) held a
symposium entitled “Advances in Assessing Adverse Epigenetic
Effects of Drugs and Chemicals” in Washington, D.C. which wassponsored by the Technical Committee for the Application of
Genomics to Mechanism-Based Risk Assessment. The goal of the
symposium was to identify gaps in knowledge and promising areas
of progress that represent opportunities where collaborative
efforts could further the utilization of epigenomic profiling in
drug and chemical safety assessment programs. In this review, we
summarize topics discussed during the workshop that are
supplemented by a review of the current literature.
2. Implications of epigenetics in various sectors involved in
safety assessments
2.1. Pharmaceutical safety
Past attention on the role of genetics in cancer has focused on
the accumulation of changes in DNA sequence. However, recent
investigations using global proteomic and genomic approaches
have suggested that alterations in both genetic and epigenetic
factors contribute to cancer development (Di Costanzo et al., 2014).
In contrast to changes in genetic sequence, epigenetic modifica-
tions can potentially be reversed or restored by therapies that
target over expressed or mutated chromatin regulatory proteins.
As a result, the pharmaceutical industry has directed efforts to
develop targeted therapies against epigenetic-modifying enzymes,
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ases (HMTs), histone demethylases (HDMs), histone acetyltrans-
ferases (HATs), and DNA methyltransferases (DNMTs). Significant
debate surrounds the potential risks that might be associated with
long-lasting drug-induced epigenetic perturbations. Factors to
consider include the duration of toxicology studies, reversibility,
gene locus-, tissue- and species-specificity, and the importance of
distinguishing between adaptive and adverse epigenetic pertur-
bations. Furthermore, differences in risk-benefit for oncology
versus non-oncology therapeutic indications need to be consid-
ered. The innovative medicines initiative (IMI) bioMARkers and
molecular tumor classification for non-genotoxic CARcinogenesis
(MARCAR) consortium have made significant progress in the
characterization of long-lasting drug-induced epigenetic pertur-
bations associated with rodent non-genotoxic hepatocarcino-
genesis via integrated epigenomic and transcriptomic profiling
(Lempiainen et al., 2011, 2013; Luisier et al., 2014; Thomson et al.,
2012, 2013). A similar strategy may provide valuable insights into
additional long-lasting toxicities such as allergen-induced T cell
responses (Chapman et al., 2014; Moggs et al., 2012).
Several epigenetic-modifying drugs have gained FDA approval
or are being utilized in ongoing clinical trial investigations.
Inhibitors of DNMTs and HDACs already received FDA approvals.
The DNMT inhibitors, 5-azacitidine and 5-aza-20-deoxycytidine,
are approved for the treatment of acute myelogenous leukemia
and myelodysplastic syndrome, and the HDAC inhibitors, romi-
depsin and vorinostat, are approved for treatment of cutaneous
and peripheral T cell lymphoma (CTCL and PTCL). Despite their
efficacy for treating cancers, the reported and common side effects
for each class included thrombocytopenia, neutropenia, anemia,
and gastrointestinal adverse events (among them are nausea,
vomiting, and diarrhea). With some HDAC inhibitors, clinically
insignificant, transient and reversible QTc prolongations have also
been previously reported. The cumulative effect of antiemetics
(serotonin receptor antagonists associated with QTc prolongation
(Fraczek et al., 2013) used during HDAC treatments might
contribute to these electrocardiographic changes. However, recent
analyses of QTc interval data obtained from CTCL and PTCL patients
that received antiemetics prior to romidepsin treatment demon-
strated that treatment with romidepsin did not markedly prolong
the QTc interval despite the use of the QTc-prolonging antiemetics
(Sager et al., 2015). For another HDAC inhibitor, belinostat, ECG
analysis did not identify any QTc prolongation (Spectrum
Pharmaceuticals, 2014).
Epigenetic-modifying drugs have the potential to promote viral
reactivation via the phenomenon of activating latent viral DNA in
the host genome. In vitro experiments indicated the role of histone
acetylation and CpG methylation in maintaining viral latency of
Epstein bar virus (EBV), cytomegalovirus (CMV), human immuno-
deficiency virus-1(HIV-1) and hepatitis B virus (HBV) (Belloni et al.,
2009; Blazkova et al., 2009; Liu et al., 2013a; Pollicino et al., 2006).
HDAC inhibitors (sodium butyrate and trichostatin A), a DNMT
inhibitor (azacitidine), or a combination treatment of HDAC and
DNMT inhibitors have been shown to activate the lytic cycles of
both EBV (Li et al., 2012) and Kaposi’s sarcoma associated
herpesvirus (KSHV) (Gorres et al., 2014) via activation of trans-
activator proteins that drive the lytic cycle. While such viral
reactivation has been shown in in vitro models, the challenge is to
determine whether viral activation due to drug-induced loss of
viral latency could present a safety risk to patients. Recent analyses
have suggested an apparent relationship between romidepsin
treatment and viral reactivation (i.e., high frequency of reactivation
of the latent EBV) in South Korean patients with a rare type of
EBV-induced T-cell lymphoma (15-day increased frequency report,
Celgene). EBV reactivation due to romidepsin in lymphoma
patients is rarely reported in Western patient populations,probably because this type of EBV-induced T cell lymphoma is
extremely rare in the West. Viral reactivation may be of therapeutic
benefit in certain instances such as the reactivation of HIV-1 from
dormancy in infected T-cells may allow anti-retroviral therapy to
become effective. Future research aimed at better understanding
transcriptional control of HIV-1 may, in theory, enable develop-
ment of combinatorial therapies that include drugs designed for
viral reactivation (Mbonye and Karn, 2014).
2.2. Environmental risk assessment in the context of transgenerational
considerations
Transgenerational epidemiology is a field that entails investi-
gation of exposure effects beyond a single generation. While
biological inheritance of a phenotype was long regarded as
inheritance of genetic sequence variation, there is increasing
appreciation for the role of exposure-induced epigenetic changes.
According to investigators participating in the Network in
Epigenetic Epidemiology, the field seeks to identify “what
exposure at which life stage in parents, grandparents, or distant
ancestors is associated with measurable phenotypic outcome in
the offspring or subsequent generations” (Pembrey et al., 2014).
Importantly, the parents that experience the epigenetic modifi-
cations may not exhibit the adverse phenotype.
Transgenerational inheritance of epigenetic modifications
begins with exposure in the F0 generation that results in
phenotypes not only through simple fetal exposures
(F1 generation) but also in the F2 or F3 generations. Current
models indicate that the majority of epigenetic modifications are
reprogrammed in developing primordial germ cells (PGCs) and
during embryogenesis (Hajkova et al., 2002; Lee et al., 2002).
However, some modifications are consistently maintained at
specific regions in developing PGCs and are delivered to subse-
quent generations (Lane et al., 2003). The study of embryogenesis
in model organisms and humans is essential to define trans-
generational phenomena and propagation, since there are still
controversies whether supposed transgenerational epigenetic
effects are truly transgenerational at least in animals and humans,
and the mechanisms of inheritance are poorly understood (Heard
and Martienssen, 2014).
Animal studies have been used to gain a broader understanding
of transgenerational inheritance of epigenetic modifications due to
environmental exposures. In addition, to separate the contribution
of the maternal uterine environment and that of the epigenome
both maternal and paternal transmission as well as embryo
transfer have been investigated (Padmanabhan et al., 2013). In the
folate cycle hypomorphic model, for example, congenital malfor-
mations were due to the epigenetic makeup, while growth
retardation was related to the uterine environment. The appear-
ance of congenital malformations independent of maternal
environment persisted for five generations, which is suggested
to be due to transgenerational epigenetic inheritance by a modality
that is yet to be identified.
In addition to transgenerational inheritance of adverse
effects, studies have also reported adaptive transgenerational
responses. One example is the adaptive wound-healing response
in rat liver. In a landmark study, it was demonstrated that F1 and
F2 offspring born to male rats that had sustained liver damage
due to carbon tetrachloride (CCl4) had inherited protective
epigenetic changes. The heritable epigenetic signatures were
found to be associated with increased hepatic expression of
antifibrogenic PPAR-g and decreased expression of profibrogenic
TGF-b. Importantly, the transgenerational mode of transmission
was found to be through the male germline, eliminating
confounding factors from the uterine environment (Zeybel
et al., 2012).
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Given recent datasets that suggest that chemically-induced
epigenetic changes may adversely impact current and future
generations, consideration has been given toward the role of
epigenetics in product safety assessment for industrial and
agricultural compounds as well. Although not generally required
by current safety assessment guidelines, chemical manufacturers
have begun to evaluate transgenerational case studies with
integration of epigenetic dose–response curves into experimental
design. These studies are intended to evaluate whether the dose-
dependency of potential transgenerational epigenetic phenomena
occurs at or below “no adverse effect levels (NOAELs)” of
traditional apical endpoints that are currently assessed in
regulatory studies. These data may be useful to eventually
determine the adequacy of the current regulatory toxicity testing
guidelines to detect adverse epigenetic effects. A case study
conducted by Dow Chemical using the fungicide vinclozolin was
recently published (Alyea et al., 2014). In utero exposure of
vinclozolin and its major metabolites act as antiandrogens, causing
male rat offspring to be demasculinized as typified by reduced
anogenital distance, retained nipples, a vaginal pouch, cleft phallus
with hypospadias, suprainguinal ectopic scrota and testes, and
altered sex accessory glands in male offspring. While transgenera-
tional research studies in rats exposed gestationally to vinclozolin
did result in adverse reproductive effects to offspring, these
occurred at doses that are 40–80 fold higher than the NOAEL and
LOAEL (lowest adverse effect level). Detailed analysis showed that
effective doses for epigenetic endpoints were covered by apical
endpoint NOAELs. It is important to note that studies done by other
investigators using the same dose of vinclozolin found no effects
on the same reproductive endpoints over four generations in rats
(Schneider et al., 2013). Reasons for the differences between
studies may include sources of variability, such as genetic stock of
rats, the role of gut microbiota, and other factors. However, taken
together, the data indicated that the risk assessment performed for
vinclozolin using apical endpoints was conservative enough to
prevent the observed epigenetic changes.
3. Model systems and biomarkers to assess epigenetic effects
Several promising model systems and biomarkers for assessing
epigenetic effects were discussed during the symposium. Selected
topics are presented in this section.
3.1. Natural genetic variation and interaction with the epigenome at
the population level
A significant knowledge gap in the field is in determination of
the natural variability in the epigenome within populations. As one
goes forward in associating epigenetic patterns with a disease, it is
essential to trace the limits of what epigenetic marks may be
considered “normal”. A substantial hurdle to the integration of
epigenetics for toxicological assessment is the current uncertainty
around what constitutes a normal, adaptive response to an
exogenous stimulus and what is an adverse, disease-associated
alteration. Investigation of dynamic variations in the epigenome
between animal strains, sexes, and ages are thus a starting point to
identify natural variability. While the studies conducted in a single
strain of inbred mice are tremendously useful in identifying basic
mechanisms, they present significant limitations in terms of
representing the breadth of variability found in the human
population. Current efforts to overcome these limitations include
the mouse Methylome Project, directed by the National Institute of
Environmental Health Sciences (NIEHS) and the National Toxicol-
ogy Program (NTP). The scope of this project is a comparativeanalysis of the methylomes in the livers of males and females in
three different inbred mouse strains with the goal of producing a
better understanding of the relationships between allele-specific
methylation patterns, regulation, and altered expression in
response to environmental stimuli. Data collected via this cross-
disciplinary effort will include information on the methylome,
genome, and transcriptome of paternal strains and F1 progeny.
These data will provide insights on epigenomic inheritance to
offspring as well as how the epigenetic landscape might differ
among genders, siblings, and strains (i.e., genetic background).
Population-based rodent models provide a means to study the
interaction between genetic sequence variation and epigenetic
modifications in the context of a xenobiotic insult. One such model
is the diversity outbred, a mouse population with genetic sequence
variation that is more extensive than comparable human
populations. Because of a low minor allele frequency (12.5% on
average), a well-powered study will require far fewer mice than
humans (Churchill et al., 2012). A recent study by French and
coauthors explored the use of diversity outbred mice as a tool to set
a benchmark dose for benzene-induced micronucleus formation in
genetically diverse populations (French et al., 2015). The authors
demonstrated that the inclusion of genetically sensitive individu-
als would result in a more conservative benchmark dose than that
suggested by genetically homogeneous B6C3F1/J mice, which are
the standard mouse model for the National Toxicology Program.
While the model provides a promising paradigm for assessing the
adverse effects of chemicals in a diverse population, to date there
have been no studies linking genetic variation to epigenetic
modifications using the diversity outbred mice. Similar efforts are
being pursued by several other public/private consortia or
partnerships, such as a recent European Chemical Industry Council
(CEFIC) Long-range Research Initiative (LRI) to define “normality of
the rodent epigenome” including outbred strains (http://cefic-lri.
org/projects/c3-ed-a-comprehensive-epigenomic-profile-of-liver-
tissue-from-rat-and-mouse/). Even in plant research, efforts in
mapping epigenomes are underway to understand plant growth,
development, and adaptation to the environment (Consortium,
2012).
With the advent of comprehensive human tissue-specific
epigenome maps (Kundaje et al., 2015), Epigenome-Wide
Association Studies (EWAS) of human populations and patient
cohorts are likely to provide additional novel insights into
mechanisms and biomarkers underlying xenobiotic responses.
For example, cigarette smoking has been linked with specific CpG
methylation alterations in the aryl hydrocarbon receptor repres-
sor gene in blood cells derived from both adult smokers and
newborn babies exposed to maternal smoking in utero (Joubert
et al., 2012; Monick et al., 2012; Shenker et al., 2013). EWAS
studies are already being extensively used to characterize human
disease states and identify potential epigenetic risk factors (Liu
et al., 2013b; Rakyan et al., 2011). Whether or not peripheral
epigenetic biomarkers (e.g., blood- or skin-derived) can help
predict patient susceptibility to drug-induced toxicities remains
to be established. EWAS might ultimately assist in designing
transgenerational studies in humans depending on the mode of
inheritance (Heijmans et al., 2009).
3.2. Non-rodent models for epigenetic assessment
As summarized in Section 2, there has been considerable
concern and controversy surrounding the potential for xeno-
biotics to cause adverse effects in subsequent generations. Similar
concerns could be applicable to targeted therapies for epigenetic
modifiers. Therefore, it is becoming increasingly important to
have improved methods for assessing the likelihood that specific
classes of xenobiotics might produce delayed effects that impact
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studies up to the F3 generation are required to reveal trans-
generational effects. However, such studies are long and therefore
expensive to conduct in mammalian species, and fit poorly into
safety assessment development paradigms. The duration of these
studies could be shortened by the use of non-mammalian models
like zebrafish that recapitulate the cell migration and pattern
formation inherent in the mammalian conceptus in an intact
organism.
Zebrafish are frequently used in toxicological studies and the
species has recently gained attention as an attractive model for
transgenerational effects of xenobiotics owing to strong conserva-
tion of gene and protein structure and function between zebrafish
and humans (Mudbhary and Sadler, 2011). Additional advantages
are ease of genetic manipulation, utility for high content imaging,
and the relatively short time frame of breeding and development.
In addition, chemical exposure to zebrafish embryos can be
monitored and standardized more effectively than rodent embryos
that are subject to maternal metabolism and differences in parity.
Increasingly, zebrafish are employed in high-throughput assays
aimed at assessing developmental morphology endpoints (Truong
et al., 2014). In addition, zebrafish are an ideal model for RNAi
studies and offer the advantage of providing a more rapid screen
when compared to generation of knockout rodent models (Gaytan
and Vulpe, 2014). Several publications have shown that trans-
generational adverse effects can be demonstrated in zebrafish
using different chemical treatments, including 2,3,7,8-tetrachlor-
odibenzo-p-dioxin (TCDD) (Baker et al., 2014), androgens (Xu et al.,
2014), and perfluorononoate (Liu et al., 2011).
3.3. Stem cells and reprogramming
Stem cell models may be employed to assess the effects of
chemicals on the differentiation process, as proteins functioning in
epigenetic pathways are very often expressed in embryonic and
adult stem cells and are involved in regulating key events during
stem cell self-renewal, differentiation, and tissue senescence
(Gifford et al., 2013; Hemberger et al.,, 2009; Paige et al., 2012;
Raveh-Amit et al., 2013; Xie et al., 2014). In embryonic stem cells,
modulation of such proteins is known to be associated with
embryonic and developmental toxicity. Adult stem cells are
distributed in most adult mammalian tissues as partially
differentiated progenitor cells and are involved in maintaining
tissue homeostasis and help with regeneration and repair during
tissue damage (Iglesias-Bartolome and Gutkind, 2011). Because
stem cells in each tissue rely on a different suite of transcription
and epigenetic factors to maintain their own particular state of
differentiation (Chen et al., 2012), modulation of epigenetic protein
targets could lead to stem cell exhaustion, bone marrow
suppression, immune suppression, gastrointestinal toxicity, and
impaired tissue regeneration and repair. Although the effect of
modulation of epigenetic targets on adult stem cell function can be
modeled in vitro, it is not practically feasible to develop assays that
would comprehensively cover multiple adult tissues. Therefore, a
more general screen based on human (or rodent) embryonic or
induced pluripotent stem cells (hESC/hiPSC) may serve as a
surrogate for adult progenitor/stem cells. Undifferentiated
hESC/iPSC could be dosed with compounds and evaluated for a
variety of differentiation and also epigenetic endpoints. A
requirement for the latter is the availability of robust differentia-
tion protocols.
3.4. Novel epigenetic biomarkers for safety assessment
The incorporation of modern molecular and “omics” technolo-
gies into regulatory decision-making has great potential toimprove risk and product safety assessment methodologies. One
promising avenue is the identification of epigenetic markers of
chronic toxicities like carcinogenesis in rodent studies that might
ultimately be translated into surrogate markers of an adverse
response in humans (Laird et al., 2013; Thomson et al., 2014).
Epigenetic marks could serve as potential biomarkers of prior
exposure of chemicals that affect the epigenome in a reliable and
dose dependent manner. There are, however, significant gaps in
the knowledge of epigenetic effects caused by xenobiotics that
need to be bridged before epigenetic signatures and biomarkers
can be introduced into risk assessment.
4. Knowledge gaps and future directions
Based on symposium presentations and discussions, several
data gaps were identified that should be addressed in order to
advance the use of epigenetics in drug and agrochemical
development and environmental risk assessment.
4.1. Dose–response analysis
There is a lack of sufficient studies that evaluate the epigenetic
effects of exposure to multiple doses of the same compound. Given
that not all toxicological responses follow a linear model, carefully
designed studies that would utilize a range of doses of the test
article are clearly needed to explore the dose–response potential of
epigenetic parameters. Multiple examples exist where testing at
high doses are not predictive of biological effect at environmen-
tally relevant doses, as is the case for numerous endocrine-
disrupting chemicals (Almstrup et al., 2002). In addition, assess-
ment of epigenetic changes at multiple dose levels may provide
key data that would enable identification of a benchmark dose for
adverse epigenetic modifications caused by xenobiotic agents.
4.2. Non-cancer endpoints
Since carcinogenesis involves epigenetic alterations, there is a
strong emphasis of current epigenetic studies on cancer causation
or therapy. However, it is becoming increasingly evident that
epigenetic changes are also associated with the pathogenesis of an
increasing number of other common disorders, such as type
2 diabetes, cardiovascular disease (Kim et al., 2010; Chen et al.,
2011), and autism, to name a few. Furthermore, associations have
been made between environmental exposures and increased risk
for certain non-cancer diseases. Examples of potential relation-
ships that have been investigated include pesticides and Parkin-
son’s disease (Pezzoli and Cereda, 2013) and persistent organic
pollutants and type 2 diabetes (Everett et al., 2007; Lee et al.,
2006). It remains a challenge to identify epigenetic alterations
associated with a specific disease and to determine if they are
causative or casual changes.
4.3. Drug development
Questions remain on how or whether safety assessment of
drugs targeting the epigenetic machinery will differ from other
classes of drugs. Potential unique risks for such drugs could
include aberrant adult stem cell differentiation including reduc-
tion of cells available for self-renewal, reactivation of latent
viruses considering the role for H3K9 methylation in maintenance
of HIV virus latency, or transgenerational effects resulting from
perturbation of imprinted gene loci. Investigation of such
potential risks are expected to be associated with specific
challenges concerning the required length of studies, inter-
species and inter-individual variability, distinction of adaptive
versus adverse effects, reversibility, and tissue specificity.
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oncological as compared to non-oncological indications will
require additional considerations.
4.4. Transgenerational safety assessment
Since new approaches for the treatment of cancer and other
disease areas are increasingly targeting epigenetic mechanisms,
concerns are rising about the potential of such drugs to cause
effects in subsequent generations. As the first epigenetics treat-
ments for cancer were shown to be effective and tolerated, these
approaches are now moving into less life-threatening indications.
Therefore, it becomes increasingly important to develop an
assessment of the likelihood, or not, that these treatments might
produce delayed effects on future generations. To reveal trans-
generational effects, multigeneration studies up to F3 are required.
Such studies are long and therefore expensive, and fit poorly into
drug development paradigms. Zebrafish may be able to help
shorten the duration of such studies, but they are not yet a widely
used model for this application. Thus one potential research area is
the development of the zebrafish model for epigenetic research
with the ultimate goal of using this model to study the potential
transgenerational effects of pharmaceuticals and chemicals. A
potential limitation of studies in zebrafish is the relevance of
findings to mammals. There are important differences in both the
mechanisms and phasing of genomic DNA methylation in
mammals and zebrafish during early development (Jiang et al.,
2013; Potok et al., 2013) and differences concerning demethylation
waves after fertilization during early development that will need to
be taken into account (Hackett and Surani, 2013).
4.5. Stem cell models
The effects of drugs and chemicals on human safety and efficacy
are ideally evaluated in humans; however, tissue availability and
suitability of current in vitro models are generally a limiting factor.
Stably transformed cell lines have multiple mutations and
epigenetic defects that could indirectly modulate or confound
epigenetic effects of drugs. In addition to supply issues, primary-
derived differentiated cells do offer the opportunity to develop
testing models which are more physiologically relevant for
humans, and which better model human disease if derived from
cells of patients via a induced pluripotent stem cell (iPSC) state
(Engle and Puppala, 2013; Pistollato et al., 2012).
Concerning chemical effects on the epigenetic network in cells,
stem cell models may be used either in their differentiated state or
during differentiation. With respect to the former, cells differenti-
ated from human iPSC may be better suited for assessment of
chemical effects on epigenetic parameters since iPSC from
different individual genotypes can be derived and then differenti-
ated into non-transformed cell types such as cardiomyocytes,
hepatocytes and neurons under defined conditions. Thus this
model system offers a unique opportunity to define intra-
individual and intra-cell type effects under non-confounding
experimental conditions. Since chromatin within different cell
types exists in different conformations, chemicals may induce
different epigenetic changes in, for example, hepatocytes or
cardiomyocytes, which may then be much better assessed in
these more coherently differentiated cells.
4.6. Determination of which epigenetic alterations are adverse
One of the most promising avenues is the identification of
epigenetic markers of toxicity, especially of chronic toxicities like
carcinogenesis, that can be further translated into surrogatemarkers of an adverse response in humans (Laird et al., 2013;
Thomson et al., 2014). However, one of the significant gaps in the
knowledge of epigenetic effects caused by xenobiotics that need to
be bridged before epigenetics can be introduced into risk
assessment is the determination of which epigenetic changes
are “adverse” versus “adaptive” and in what contexts do the
changes exert a deleterious effect on an individual. To fulfill this
need, more data are needed on epigenetic alterations that occur in
target tissues and blood in the context of exposure to a wide variety
of xenobiotic agents that span multiple modes of action. Such
studies would include several doses and time points to derive a
comprehensive picture of the time course of appearance (and
possibly resolution) of epigenetic alterations.
5. Conclusions
Significant progress has been made in epigenetic research and
in our understanding of the epigenetic effects associated with
exposure to drugs and chemicals in the last several years.
Technological developments, including novel methodologies and
approaches for evaluation of existing epigenetic endpoints, as well
as establishment of new epigenetic parameters, promise to
significantly increase the robustness of these methods to allow
effective application in safety assessment. The HESI symposium on
advances in assessing adverse epigenetic effects of drugs and
chemicals provided a forum to review the primary advances in
epigenetic research and to discuss major concerns and knowledge
gaps that need to be addressed before epigenetic endpoints may be
used in toxicological evaluations. Natural variability and dynamic
variation in the epigenome between strains, sexes, and ages
present challenges in defining the line between “healthy” and
“diseased” epigenomes. Specific epigenetic end-points that can be
utilized in safety assessment as well as assays and model systems
for assessment of these parameters need to be further identified
and evaluated for consistent implementation. These gaps could be
bridged by consortial efforts that generate the necessary compre-
hensive data sets.
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